ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $94.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective lifted by HC Wainwright from $87.00 to $94.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 48.99% from the company’s previous close. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2024 earnings at $0.75 EPS and FY2024 earnings at $3.34 EPS.

ANIP has been the subject of several other reports. Guggenheim restated a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Capital One Financial started coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $82.75.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $63.09 on Wednesday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 39.43 and a beta of 0.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. The stock’s fifty day moving average price is $64.25 and its 200 day moving average price is $61.60. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The business had revenue of $137.43 million for the quarter, compared to analyst estimates of $125.01 million. As a group, equities research analysts forecast that ANI Pharmaceuticals will post 3.34 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 5,000 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total value of $317,900.00. Following the completion of the transaction, the chief financial officer now owns 161,968 shares in the company, valued at approximately $10,297,925.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total value of $317,900.00. Following the sale, the chief financial officer now directly owns 161,968 shares of the company’s stock, valued at $10,297,925.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Muthusamy Shanmugam sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $58.90, for a total value of $1,178,000.00. Following the transaction, the chief operating officer now directly owns 682,620 shares of the company’s stock, valued at $40,206,318. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 176,688 shares of company stock worth $11,408,863. 12.70% of the stock is owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of ANIP. Charles Schwab Investment Management Inc. lifted its stake in ANI Pharmaceuticals by 287.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after buying an additional 109,015 shares in the last quarter. Deutsche Bank AG lifted its position in shares of ANI Pharmaceuticals by 50.7% in the third quarter. Deutsche Bank AG now owns 7,643 shares of the specialty pharmaceutical company’s stock valued at $444,000 after acquiring an additional 2,570 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of ANI Pharmaceuticals by 13.4% in the third quarter. Rhumbline Advisers now owns 39,684 shares of the specialty pharmaceutical company’s stock worth $2,304,000 after acquiring an additional 4,700 shares during the last quarter. Invesco Ltd. increased its position in shares of ANI Pharmaceuticals by 185.4% during the third quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after purchasing an additional 220,690 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at $541,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.